Quince Therapeutics(QNCX)

Search documents
Quince Therapeutics(QNCX) - 2021 Q4 - Annual Report
2022-03-01 22:01
FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38890 Cortexyme, Inc. (Exact name of registrant as specified in its Chart ...
Quince Therapeutics(QNCX) - 2021 Q3 - Quarterly Report
2021-10-29 13:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-38890 Cortexyme, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-10 ...
Quince Therapeutics(QNCX) - 2021 Q2 - Quarterly Report
2021-08-06 20:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) Commission File Number: 001-38890 Cortexyme, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-1024039 ( State or other jurisdiction of incorporation or organization) 269 East Grand Ave. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX ...
Quince Therapeutics(QNCX) - 2021 Q1 - Quarterly Report
2021-05-06 20:19
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-38890 Cortexyme, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-102403 ...
Cortexyme (CRTX) Investor Presentation - Slideshow
2021-03-17 17:07
March 2021 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cortexyme's own internal estimates and research. While Cortexyme believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any ...
Quince Therapeutics(QNCX) - 2020 Q4 - Annual Report
2021-03-01 21:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Cortexyme, Inc. (Exact name of registrant as specified in its Charter) Delaware 90-1024039 (State or other jurisdiction of incorporation or organization) 269 East Grand Ave. South San Francisco, California 94080 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identif ...
Quince Therapeutics(QNCX) - 2020 Q3 - Quarterly Report
2020-11-12 21:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-38890 Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- | - ...
Quince Therapeutics(QNCX) - 2020 Q2 - Quarterly Report
2020-08-14 20:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Cortexyme, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-1024039 ( State or other jurisdiction of incorporation or organization) 269 East Grand Ave. South San Francisco, California 94080 (Address of principal executive offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REP ...
Cortexyme (CRTX) Investor Presentation - Slideshow
2020-06-03 22:10
June 2020 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cortexyme's own internal estimates and research. While Cortexyme believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any ...
Quince Therapeutics(QNCX) - 2020 Q1 - Quarterly Report
2020-05-12 20:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR (Exact Name of Registrant as Specified in its Charter) Delaware 90-1024039 ( State or other jurisdiction of incorporation or organization) 269 East Grand Ave. South San Francisco, California 94080 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification ...